EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

High DCR and Better Survival in Patients with Advanced or Metastatic Gastric Cancer Receiving Anti-Angiogenic TKI plus Chemotherapy: A Real-World Study

Caiyun Nie, Huifang Lv, Beibei Chen, Weifeng Xu, Jianzheng Wang, Saiqi Wang, Yingjun Liu, Yunduan He, Jing Zhao, Xiaobing Chen iD

Technology in Cancer Research & Treatment · 2023

DOI: 10.1177/15330338221150561 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Technology in Cancer Research & Treatment, 2023. Verfasst von Caiyun Nie und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Affiliated Cancer Hospital of Zhengzhou University, 377327Henan Cancer Hospital, Zhengzhou, China. Hauptthemen laut MEDLINE: Antineoplastic Agents, Stomach Neoplasms, Angiogenesis Inhibitors, Tyrosine Kinase Inhibitors. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: 1000 Talents Program of Central plains, Young and Middle-aged Health and Technology Innovation Leading Talent Project of Henan Province, Sate Key Laboratory of Esophageal Cancer Prevention & Treatment.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

This study was carried out to assess the efficacy and drug toxicity of anti-angiogenic tyrosine kinase inhibitor (TKI) plus chemotherapy as second-line or above therapeutic regime in advanced or metastatic gastric cancer patients.

Methods

From November 2017 to April 2020, advanced or metastatic gastric cancer patients who have failed from prior treatment and received apatinib combined with irinotecan or irinotecan treatment were analyzed. The primary observed indicator was progression-free survival (PFS). Objective: response rate (ORR), disease control rate (DCR), overall survival (OS), and drug toxicity were also evaluated.

Results

26 patients received apatinib combined with irinotecan and 29 patients received irinotecan. The ORR in the combination therapy and monotherapy population was 26.9% and 17.2%, respectively. The DCR in the apatinib combined with irinotecan group was higher than in irinotecan monotherapy population (80.8% vs 55.2%, P = .043). Median PFS was 4.2 months in the combination group and 3.3 months in the monotherapy group ( P = .020). Median OS was 8.0 months in the combination group and 5.9 months in the monotherapy group ( P = .048). Except for ECOG PS 2, PFS and OS were generally consistent across subgroups by sex, age, number of metastatic sites and primary tumor site. The incidence of Grade 3–4 adverse events in combination and monotherapy group was 23.1% and 20.7%, respectively. In apatinib combined with irinotecan group, adverse events that were attributed to apatinib were secondary hypertension (in seven patients, 26.9%), hand-foot syndrome (5,19.2%), and proteinuria (5, 19.2%). Univariate analysis demonstrated that secondary hypertension was considered to be a favorable factor ( P = .040) for longer OS in combination therapy group.

Conclusions

Compared with chemotherapy alone, anti-angiogenic TKI plus chemotherapy showed better PFS, OS and DCR in advanced or metastatic gastric cancer as second-line or above therapy, with a tolerable and manageable safety profile.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic AgentsStomach NeoplasmsAngiogenesis InhibitorsTyrosine Kinase InhibitorsHumansHypertensionIrinotecanNeoplasm Metastasis

Stichwörter der Autor:innen

anti-angiogenicchemotherapyefficacygastric cancergastroesophageal junction adenocarcinoma

Substanzen

Antineoplastic AgentsIrinotecanAngiogenesis InhibitorsTyrosine Kinase Inhibitors

Autor:innen und Institutionen

  • Department of Medical Oncology, Affiliated Cancer Hospital of Zhengzhou University, 377327Henan Cancer Hospital, Zhengzhou, China.
  • State Key Laboratory of Esophageal Cancer Prevention & Treatment, Zhengzhou University, Zhengzhou, China.
  • Henan Engineering Research Center of Precision Therapy of Gastrointestinal Cancer, Zhengzhou, China.
  • Zhengzhou Key Laboratory for Precision Therapy of Gastrointestinal Cancer, Zhengzhou, China.
  • Department of General Surgery, Affiliated Cancer Hospital of Zhengzhou University, 377327Henan Cancer Hospital, Zhengzhou, China.

ORCID-Profile: Xiaobing Chen

Förderung

  • 1000 Talents Program of Central plains
  • Young and Middle-aged Health and Technology Innovation Leading Talent Project of Henan Province
  • Sate Key Laboratory of Esophageal Cancer Prevention & Treatment
  • Medical Science and Technique Foundation of Henan Province (
  • Medical Science and Technique Foundation of Henan Province

Zitieren

APA

Nie, C., Lv, H., Chen, B., Xu, W., Wang, J., Wang, S., Liu, Y., He, Y., Zhao, J., & Chen, X. (2023). High DCR and Better Survival in Patients with Advanced or Metastatic Gastric Cancer Receiving Anti-Angiogenic TKI plus Chemotherapy: A Real-World Study. Technology in Cancer Research & Treatment. https://doi.org/10.1177/15330338221150561

Vancouver

Nie C, Lv H, Chen B, Xu W, Wang J, Wang S, et al. High DCR and Better Survival in Patients with Advanced or Metastatic Gastric Cancer Receiving Anti-Angiogenic TKI plus Chemotherapy: A Real-World Study. Technology in Cancer Research & Treatment. 2023. doi:10.1177/15330338221150561

BibTeX
@article{Nie2023,
  author = {Nie, Caiyun and Lv, Huifang and Chen, Beibei and Xu, Weifeng and Wang, Jianzheng and Wang, Saiqi and Liu, Yingjun and He, Yunduan and Zhao, Jing and Chen, Xiaobing},
  title = {High DCR and Better Survival in Patients with Advanced or Metastatic Gastric Cancer Receiving Anti-Angiogenic TKI plus Chemotherapy: A Real-World Study},
  journal = {Technology in Cancer Research & Treatment},
  year = {2023},
  doi = {10.1177/15330338221150561}
}
Kostenlos starten →